Funds are concentrated in a few names with volume,


The contract market clearly shows a pursuit of strong momentum.
$TRUTH +37.2%
Ranked first, with a trading volume of $205M.
Open interest (OI) has surged by 105.4%.
This is not a pulse without volume,
More like funds suddenly rushing in.
$JCT +36.5%
Ranked second, with a funding rate of 0.073%.
OI increased by 67.0% in one go.
The increase is rapid but the volume is only $27M,
The small-cap elasticity is significantly amplified.
$LAB +36.3%
Ranked third, with a trading volume of $450M.
OI increased by 30.4%, with a long-short ratio of 0.56.
The trading is active, and disagreements still exist,
This kind of market is more interesting than just chasing highs unilaterally.
$COS +30.3%
Ranked fourth, complete contract data is missing.
Just looking at the increase, it has entered the top tier.
It belongs to the strong expansion follow-up names,
But the market details still need data to confirm.
$INJ +23.2%
Ranked fifth, complete contract data is missing.
The increase lags behind the top three but still shows strength.
More like high-beta spillover outside the main line,
The continuation depends on whether the trading volume can catch up.
Top 4-10 briefly:
COS +30.3%, INJ +23.2%,
UB +23.1%, VELVET +21.3%,
BILL +19.3%, Q +18.3%,
AVAAI +16.1%.
Candidates for short squeeze:
TRUTH, JCT, LAB all show
Rapid influx of open interest (OI) and squeezing signals.
Especially TRUTH, which is the most exaggerated,
Funds are not slowly probing,
But directly piling up positions.
Overall assessment:
Today is a day when a few strong stocks attract attention.
Focus on the continuation of TRUTH,
And also on LAB, which has volume divergence.
Generated using AI model.
Claude is AI and can make mistakes.
Please double-check responses.
Generated using Claude Opus 4.7 model.
Claude is AI and can make mistakes.
Please double-check responses.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin